Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-α as second-line treatment of advanced transitional cell cancer of the urothelial tract

Annals of Oncology

Volumn 11, Issue 11, 2000, Pages 1391-1394

  De Mulder, P H M ^a   Theodore, C ^b   Sella, A ^c   Koriakine, O ^d   Sternberg, C N ^e   Collette, L ^f   De Balincourt, C ^f  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c TEL AVIV UNIVERSITY   (Israel)

^d MEDICAL RADIOLOGICAL RESEARCH CENTER   (Russian Federation)

^e Foundation Vincenzo Pansodoro   (Italy)

^f EORTC DATA CENTER   (Belgium)

Author keywords

Chemotherapy; Interferon; Transitionall cell carcinoma; Urothelial tract

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; FLUOROURACIL;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; MALE; METASTASIS; MORTALITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; UROGENITAL TRACT TUMOR;

EID: 0033639226     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026589120989     Document Type: Article

References (20)

1. Chemotherapy of urothelial tract cancer. Memorial Sloan-Kettering Cancer Center experience
2. The chemotherapy of advanced bladder cancer
3. Gemcitabine in bladder cancer
4. Pacltaxel and carboplatin in bladder cancer. Recent developments
5. A randomized trial of cisplatin versus cisplatin plus metotrexate in advanced cancer of the urothelial tract
6. Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer. A South Eastern Cancer Study Group Trial
7. A comparison of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Cooperative Group A Study
8. Randomized phase II study of methotrexate, cisplatin and methotrexate, cisplatin and vinblastine in patients with advanced transitional carcinoma of the bladder
9. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional-cell carcinoma of the urothelium: Efficay patterns of response and relapse
10. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
11. A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors
12. Combination chemotherapy in the treatment of advanced urothelial tumours
13. Interferons as biomodulators of fluoropyrimidines in the treatment of cancer
14. Treatment of chemotherapy refractory metastatic urothelial tumors. Review
15. A 61% response rate with 5-FU, interferon-α2b and cisplatin in metastatic chemotherapy refractory transitional-cell carcinoma
16. Optimal two-stage designs for phase II clinical trials
17. Nonparametric estimation from incomplete observations
18. 5-Fluorouracil, Interferon-α2b and cisplatin (FAP) for advanced urothelial cancer. A phase II study
19. Long-term survival in metastatic transitionall-cell carcinoma and prognostic factors predicting outcome of therapy
20. Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (MI): A clinical phase II study